Ampalaya For Non-Insulin Dependent Diabetes

INVENTORS: NIRPROMP

OVERVIEW: The Philippines is an emerging hotspot for diabetes.  There are about 6 million diabetic patients in the country and many more who are yet to be diagnosed. Diabetes is a chronic condition which requires daily maintenance medicines to prevent morbidity, complications and mortality. Poor control of blood sugar leads to end organ damage which may include poor kidney function, loss of sight and amputations. 

TECHNOLOGY FEATURES AND SPECIFICATIONS: Ampalaya (Momordica charantia) is also known as bitter melon or bitter gourd. In the Philippines, traditionally uses include those for cough, colds, asthma, as emetic especially in the newborn, for colic, stomach ache diabetes, anemia, fever, malaria, ringworm, and wounds.

Several clinical trials involving adult patients with non insulin dependent diabetes mellitus showed that using Ampalaya tablet there was decreased fasting plasma glucose from the 3rd week from the start of therapy. Decrease in glucose from the 3rd to the 12th week was 8.6-40.8% comparable to glibenclamide.   HbA1c also decreased from 24.4-40% from the 3rd to the 12th week, also comparable to Glibenclamide. Since human trials have been performed for this product (unlike food supplements) the correct dose is known as well as onset of action and safety information.

Active components have been identified in ampalaya including several cucurbitane tripertenoids.  Several mechanisms of action have been proposed such as insulin secretagogue effect, stimulation or peripheral and skeletal muscle glucose and inhibition of intestinal glucose uptake utilization.  More likely it is a combination of actions due to the numerous active compounds present.  In Philippine studies, the leaves of the Makiling variety have the most potent anti-hyperglycemic activity, and this is being utilized in this formulation.

The Ampalaya herbal medicine is available as a 500 mg tablet. 

INDICATIONS: Ampalaya is indicated for the treatment of non insulin dependent diabetes mellitus. It is given at 100 mg/kg/day in 2 divided doses, I hour before meals. It is should only be used under the supervision of a physician and with regular blood glucose monitoring

MARKET TRENDS AND OPPORTUNITIES: Diabetes and metabolic syndromes are increasingly common in the Philippines. Ampalaya has been marketed as a food supplement successfully, thus an herbal medicine which has proven efficacy and safety through human trials would be easily accepted.

CUSTOMER BENEFITS: Ampalaya is an affordable, herbal medicine to treat diabetes. It was developed by Filipino researchers from Filipino plants to boost the Philippine Pharmaceutical Industry, provide new cash crops for farmers and offer Filipinos medical and financial benefits.

STATUS: The patent for this product has been secured. We are in need of pharmaceutical companies willing to produce, manufacture and distribute the product in the Philippine market.